Chengdu HuaRenKang Biotechnology

Chengdu HuaRenKang Biotechnology is a clinical-stage biopharmaceutical company based in Chengdu, China, specializing in the discovery and development of innovative peptide-based therapeutics for metabolic diseases. The company's primary focus is on multi-target agonists, including dual GLP-1/GIP and triple GLP-1/GIP/Glucagon receptor agonists, designed to address obesity, type 2 diabetes, and related metabolic disorders. HuaRenKang utilizes a proprietary technology platform to optimize the half-life and potency of peptide candidates, aiming to provide more effective and convenient treatment options. Their lead candidate, HRK-001, is currently undergoing clinical evaluation, positioning the company as a competitive player in the rapidly evolving metabolic drug market.